DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Loglio A, Ferenci P, Uceda Renteria SC. et al.
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
J Hepatol 2022;
76 (02) 464-469
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.